Xtalks hosts the live webinar “ALS Biomarkers in Drug Development,” on Tuesday, June 22, 2021 at 11am EDT (4pm BST/UK).

In this free webinar, industry experts will provide an overview of different types of ALS biomarkers, how ALS biomarkers should be chosen based on the relevance to the mechanism of action and why their use in ALS trials should be a serious consideration. They will also discuss how some biomarkers in ALS research are more valuable than others at this time, as well as the application of ALS biomarkers in drug development, according to a media release from Xtalks.

The first part of the webinar will provide an overview of ALS biomarkers, both fluid-based (blood, urine and cerebrospinal fluid) and non-fluid based (electrophysiology and PET/imaging). Specifically, the fluid-based ALS biomarkers and topics to be individually covered include genetic markers, cellular markers of neurodegeneration (markers of axon injury, neurofilaments), markers of inflammation and oxidative stress and exploratory miRNA markers.

In addition, the group will talk about the application of ALS biomarkers in drug development, addressing which are most useful and best translate in clinical research and in assessing a drug’s effect on the disease.

The panel will touch on areas of struggle where there is lack of clarity and where researchers are not certain which biomarkers are the leads at this time. There are questions moving forward including where the gaps exist in terms of ALS biomarkers.

Finally, the panel will make specific and even controversial recommendations regarding ALS biomarkers in clinical trials. Areas to be addressed include which are must-haves in trials, which are most costly, and which are operator-dependent, as well as the ramifications in clinical research, the release continues.

Speakers will include Ignazio Di Giovanna, PhD, Vice-President, Europe, Atlantic Research Group; Toby Ferguson, MD, PhD, Vice-President, Head Neuromuscular Unit, Biogen; and Angela Genge, MD, Executive Director, Clinical Research Unit (CRU), Montreal Neurological Institute.

For more information and to register, visit Xtalks.

[Source(s): Xtalks, PRWeb]